Browsing by Author "Paridaens, R."

Now showing items 1-4 of 4

    • Article  

      Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study 

      Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H. M.; Pavlidis, Nicholas; Verweij, J.; Sessa, Cristiana; Kaye, Stanley B.; Roelvink, M.; Wanders, J.; Hanauske, A. R. (2000)
      Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November ...
    • Article  

      Phase II clinical trials with rhizoxin in breast cancer and melanoma 

      Hanauske, A. R.; Catimel, G.; Aamdal, S.; Huinink, W. W. Ten Bokkel; Paridaens, R.; Pavlidis, Nicholas; Kaye, Stanley B.; Velde, A. Te; Wanders, J.; Verweij, J. (1996)
      Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose ...
    • Article  

      Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies 

      Schellens, J. H. M.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, Stanley B.; Dombernowsky, P.; Paridaens, R.; Oosterom, A. T. Van; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, Nicholas; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, Cristiana; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R. (2002)
      Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic ...
    • Article  

      Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 

      Schellens, J. H. M.; Dombernowsky, P.; Cassidy, J.; Epelbaum, R.; Dirix, L.; Cox, E. H.; Wanders, J.; Calabresi, F.; Paridaens, R.; Monfardini, S.; Wolff, J.; Loos, W. J.; Verweij, J.; Pavlidis, Nicholas; Hanauske, A. R. (2001)
      Population pharmacokinetic-dynamic analysis was prospectively integrated in the clinical phase II programme of EO9 to determine the population pharmacokinetic profile in a larger population of patients, to estimate individual ...